Illumina, Inc. (NASDAQ:ILMN) has earned a consensus recommendation of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $346.35.

ILMN has been the subject of several analyst reports. Bank of America restated a “buy” rating and set a $355.00 target price on shares of Illumina in a report on Wednesday, January 30th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $355.00 target price for the company in a report on Tuesday, October 23rd. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the company from $340.00 to $370.00 in a report on Thursday, January 3rd. Morgan Stanley dropped their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a report on Monday, January 7th. Finally, Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a research report on Friday, January 25th.

In other news, insider Francis A. Desouza sold 3,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $345.90, for a total value of $1,037,700.00. Following the completion of the transaction, the insider now owns 65,443 shares of the company’s stock, valued at approximately $22,636,733.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $280.11, for a total value of $34,733.64. Following the completion of the transaction, the senior vice president now directly owns 6,879 shares of the company’s stock, valued at approximately $1,926,876.69. The disclosure for this sale can be found here. Insiders have sold a total of 39,247 shares of company stock valued at $12,057,866 in the last ninety days. 0.54% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Financial Enhancement Group LLC bought a new position in Illumina during the 3rd quarter valued at approximately $400,000. Nan Shan Life Insurance Co. Ltd. bought a new position in Illumina during the 3rd quarter valued at approximately $52,099,000. Handelsbanken Fonder AB bought a new position in Illumina during the 3rd quarter valued at approximately $8,442,000. Hall Laurie J Trustee increased its position in Illumina by 61.8% during the 3rd quarter. Hall Laurie J Trustee now owns 890 shares of the life sciences company’s stock valued at $327,000 after buying an additional 340 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in Illumina by 18.2% during the 3rd quarter. Pacer Advisors Inc. now owns 13,597 shares of the life sciences company’s stock valued at $4,991,000 after buying an additional 2,092 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Shares of ILMN traded up $1.07 during midday trading on Wednesday, reaching $285.17. The stock had a trading volume of 160,999 shares, compared to its average volume of 1,004,987. Illumina has a 12-month low of $210.08 and a 12-month high of $372.61. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $42.34 billion, a P/E ratio of 49.85, a PEG ratio of 2.03 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Illumina had a return on equity of 24.51% and a net margin of 24.79%. The firm had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. During the same quarter in the previous year, the company posted $1.44 earnings per share. Illumina’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, equities research analysts predict that Illumina will post 6.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Recommended Story: Debt-To-Equity Ratio

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.